Concord Biotech reported a 25% YoY revenue growth to Rs 309.1 crore for Q2 FY27, backed by strong performances in API and formulation segments. Despite a 400 bps contraction in gross margins due to higher input costs, the company maintains a robust zero-debt balance sheet with Rs 445 crore in cash. Management announced a 1:1 bonus issue, signaling confidence in long-term growth driven by new injectable facilities and US market expansion.
Concord Biotech Q2 Revenue Jumps 25% To Rs 309.1 Crore
1:1 Bonus Issue Approved As Revenue Hits Rs 566.6 Crore In H1
Reader Takeaway: Top-line growth remains strong, but investors should watch for margin recovery as new injectable facilities scale up.
What just happened
Concord Biotech has announced a 1:1 bonus issue alongside its Q2 FY27 financial results. The company reported a revenue of Rs 309.1 crore, marking a 25% year-on-year increase. While the top line expanded, the company experienced a 400 basis point contraction in gross margins, which stood at 76.2%. The firm maintains a strong financial position with a zero-debt status and cash reserves totaling Rs 445 crore.
Why this matters
The expansion into high-value segments, specifically injectables and US distribution via the Stellon platform, remains the core growth narrative. Management noted that while short-term margin pressure persists due to elevated raw material costs and facility start-up expenses, the underlying business momentum is robust. Adjusting for new facility costs, EBITDA margins would have been 37.1%, closer to the historical 38-40% range.
Operations and Strategy
Facility utilization levels are currently being monitored, with the new Unit IV (Injectable) operating at 5% capacity, which is expected to ramp up in the second half of the year. The company has also launched 'Inspira,' a dermatology division, targeting Rs 400-500 crore in revenue over the next 4-5 years. Management expects FY27 growth to exceed their historical 18% average.
Risks to watch
Execution risk remains the primary concern. The company's goal of returning to a 38-40% margin band is dependent on the successful scaling of the injectables business and securing customer contracts for the Stellon platform. Sustained raw material cost inflation could continue to weigh on short-term profitability.
What to track next
Investors should look for updates on capacity utilization rates across units, particularly the growth of the injectable business and the revenue contribution from the US distribution subsidiary in H2.